Topping R M, Craven A H
Biochem J. 1979 Feb 1;177(2):501-8. doi: 10.1042/bj1770501.
Interactions between the serine proteinase trypsin and the protein proteinase inhibitors in human blood were expressed in terms of a coupled set of non-linear differential equations, which has been solved for each of 110 samples of serum obtained from colleagues and from a variety of hospital sources. Optimization of nine unknown theoretical parameters and 21 experimental rate measurements of the hydrolytic activity of trypsin in free and bound states after admixture with various amounts of a given serum was achieved by an iterative procedure using initial estimates of the parameters derived from the "four-straight-line" model described in the preceding paper [Topping & Seilman (1979) Biochem. J. 177, 493--499.] Such a procedure yielded the following information for each sample of serum examined: (a) the concentrations of alpha 1-antitrypsin and alpha 2-macroglobulin; (b) the unequivocal assignment of alpha 2-macroglobulin into one of seven categories on the basis of trypsin binding in two kinetically differentiated modes (alpha and beta); (c) the hydrolytic activities of trypsin (versus Bz-Arg-OEt) when bound to alpha 1-antitrypsin, and to alpha 2-macroglobulin in the alpha- and beta-modes. Molecular interpretations of the binding of trypsin to alpha 2-macroglobulin are discussed and the potential clinical value of recognizing the nature of such binding is reported.
丝氨酸蛋白酶胰蛋白酶与人血液中的蛋白质蛋白酶抑制剂之间的相互作用,用一组耦合的非线性微分方程来表示。对于从同事和各种医院来源获得的110份血清样本,均已求解该方程组。通过迭代程序实现了九个未知理论参数的优化以及在与不同量的给定血清混合后,对胰蛋白酶在游离和结合状态下水解活性的21次实验速率测量。该迭代程序使用了根据前文[托普金和塞尔曼(1979年)《生物化学杂志》第177卷,第493 - 499页]所述的“四条直线”模型得出的参数初始估计值。对于所检测的每份血清样本,这样的程序得出了以下信息:(a) α1 - 抗胰蛋白酶和α2 - 巨球蛋白的浓度;(b) 根据胰蛋白酶以两种动力学上有差异的模式(α和β)结合,将α2 - 巨球蛋白明确归为七种类别之一;(c) 胰蛋白酶与α1 - 抗胰蛋白酶结合以及与α2 - 巨球蛋白在α和β模式下结合时的水解活性(相对于Bz - Arg - OEt)。文中讨论了胰蛋白酶与α2 - 巨球蛋白结合的分子解释,并报告了认识这种结合性质的潜在临床价值。